Lupus & antiphospholipid syndrome
The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (neuropsychiatric SLE (NPSLE)): a retrospective cohort study of 386 patients with NPSLE
An erratum to this article was published (Arthritis Res Ther, 29 Apr 2023 ↗)
Authors' conclusion
Intrathecal treatment of methotrexate and dexamethasone was associated with a more favorable prognosis of NPSLE
Study context
- Population
- Hospitalized patients with NPSLE
- Participants
- 386 patients147 propensity score-matched pairs
- Exposure
- Intrathecal MTX and dexamethasone vs no intrathecal treatment
- Intrathecal treatmentn = 194
- Outcome
- Time free from NPSLE relapse or death
Methodological detailspropensity score-matched, multivariate logistic regression, Cox regression
- Propensity score-matched
- Multivariate logistic regression
- Cox regression
Main finding
As reported in the abstract
Survival free from NPSLE relapse
- Higher probability of survival and being free from NPSLE relapse with intrathecal treatment
- Intrathecal treatment vs Control treatment: P = 0.042 by log-rank test
- Intrathecal treatment vs Control treatment: P = 0.032 by log-rank test
Observational data: associations, not effects.
Further findings
Baseline SLEDAI-2K score
P < 0 .001
Methylprednisolone pulse therapy received
P < 0.001
- Prognosis in subgroup with increased CSF protein
- P < 0.001
Prognosis in subgroup with increased CSF protein
- Positive influence of intrathecal treatment on prognosis
Original publication
The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE. Arthritis Res Ther. Published 28 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →